(Q35895188)

11 August 2017

1 reference

title

Ximelagatran: an oral direct thrombin inhibitor (English)

1 reference

11 August 2017

William E Dager

1

1 reference

11 August 2017

Thomas G Vondracek

series ordinal

2

1 reference

11 August 2017

Bruce A McIntosh

series ordinal

3

1 reference

11 August 2017

Edith A Nutescu

series ordinal

4

1 reference

11 August 2017

language of work or name

English

0 references

publication date

21 September 2004

1 reference

Annals of Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

38

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

1881-1897

1 reference

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

11 August 2017

cites work

1 reference

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

21 January 2018

1 reference

Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug

21 January 2018

1 reference

Direct thrombin inhibitors for anticoagulation

21 January 2018

1 reference

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects

21 January 2018

1 reference

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis

21 January 2018

1 reference

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

21 January 2018

1 reference

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran

21 January 2018

1 reference

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

21 January 2018

1 reference

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

21 January 2018

1 reference

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

21 January 2018

1 reference

Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation

21 January 2018

1 reference

The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

21 January 2018

1 reference

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

21 January 2018

1 reference

A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.

21 January 2018

1 reference

No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.

21 January 2018

1 reference

Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?

21 January 2018

1 reference

No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran

21 January 2018

1 reference

Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement

21 January 2018

1 reference

Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty

21 January 2018

1 reference

Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators

21 January 2018

1 reference

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

21 January 2018

1 reference

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

21 January 2018

1 reference

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

21 January 2018

1 reference

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

21 January 2018

1 reference

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.

21 January 2018

1 reference

Antithrombotic therapy for venous thromboembolic disease

21 January 2018

1 reference

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

21 January 2018

1 reference

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

21 January 2018

1 reference

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism

21 January 2018

1 reference

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

21 January 2018

1 reference

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

21 January 2018

1 reference

Antithrombotic therapy in atrial fibrillation

21 January 2018

1 reference

Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators

21 January 2018

1 reference

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

21 January 2018

1 reference

Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention

21 January 2018

1 reference

Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study

21 January 2018

1 reference

A comparison of rate control and rhythm control in patients with atrial fibrillation

21 January 2018

1 reference

Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities.

21 January 2018

1 reference

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

21 January 2018

1 reference

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).

21 January 2018

1 reference

Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study

21 January 2018

1 reference

Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina

21 January 2018

1 reference

Warfarin, aspirin, or both after myocardial infarction

21 January 2018

1 reference

Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial

21 January 2018

1 reference

Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial

21 January 2018

1 reference

Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.

21 January 2018

1 reference

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

21 January 2018

1 reference

Argatroban therapy for antithrombin deficiency and mesenteric thrombosis: case report and review of the literature

21 January 2018

1 reference

Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis

21 January 2018

1 reference

Pharmacotherapy of heparin- induced thrombocytopenia

21 January 2018

1 reference

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

21 January 2018

1 reference

Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values

21 January 2018

1 reference

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

21 January 2018

1 reference

Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.

21 January 2018

1 reference

Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor

21 January 2018

1 reference

Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing

21 January 2018

1 reference

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence

21 January 2018

1 reference

Initiating warfarin therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E078

1 reference

11 August 2017

1 reference